Previously, CCL3, 5 and 18 serum levels have been linked to cardiovascular disease (secondary events in early follow-up, refractory UAP, and ACS) and have been shown to be expressed by atherosclerotic plaque. This evidence concerns the gene CCL3 and cardiovascular disorder.